Pathogenic Escherichia coli and food handlers in luxury hotels in Nairobi, Kenya

Travel Medicine and Infectious Disease
Abel O OnyangoMusa O Ng'ayo

Abstract

The epidemiology and virulence properties of pathogenic Escherichia coli among food handlers in tourist destination hotels in Kenya are largely uncharacterized. This cross-sectional study among consenting 885 food handlers working in nine luxurious tourist hotels in Nairobi, Kenya determined the epidemiology, virulence properties, antibiotics susceptibility profiles and conjugation abilities of pathogenic Escherichia coli. Pathogenic Escherichia coli was detected among 39 (4.4%) subjects, including 1.8% enteroaggregative Escherichia coli (EAEC) harboring aggR genes, 1.2% enterotoxigenic Escherichia coli (ETEC) expressing both LT and STp toxins, 1.1% enteropathogenic Escherichia coli (EPEC) and 0.2% Shiga-like Escherichia coli (EHEC) both harboring eaeA and stx2 genes respectively. All the pathotypes had increased surface hydrophobicity. Using multivariate analyses, food handlers with loose stools were more likely to be infected with pathogenic Escherichia coli. Majority 53.8% of the pathotypes were resistant to tetracycline with 40.2% being multi-drug resistant. About 85.7% pathotypes trans-conjugated with Escherichia coli K12 F(-) NA(r) LA. The carriage of multi-drug resistant, toxin expressing pathogenic Escherichia coli by t...Continue Reading

References

Nov 24, 1979·Nucleic Acids Research·H C Birnboim, J Doly
Dec 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S TamatsukuriT Miwatani
Nov 1, 1991·Journal of Medical Microbiology·J J BorregoA E Toranzo
May 1, 1989·Public Health·T Oteri, E E Ekanem
Jan 1, 1988·Gut·D A Burke, A T Axon
Aug 1, 1996·American Journal of Public Health·J TildenJ G Morris
Nov 22, 1997·Emerging Infectious Diseases·F K KäfersteinD W Bettcher
Feb 11, 1998·Clinical Microbiology Reviews·J P Nataro, J B Kaper
Oct 17, 1998·Journal of Travel Medicine·F F ReinthalerE Marth
Oct 31, 1998·Applied and Environmental Microbiology·C A AdamsD McIntosh
Dec 29, 1998·Emerging Infectious Diseases·S M Parry, R L Salmon
Mar 19, 1999·Emerging Infectious Diseases·R M HardieL R Bartlett
May 18, 1999·Bulletin of the World Health Organization·F Käferstein, M Abdussalam
Sep 16, 1999·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·S YamadaY Kudoh
Nov 9, 2000·The Journal of Infectious Diseases·J VilaJ P Nataro
Dec 9, 2000·International Journal of Medical Microbiology : IJMM·M J Farthing
Oct 26, 2001·The Journal of Infection·M R EvansM Z Morgan
Apr 30, 2003·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Hind I ShaheenLeonard F Peruski
May 21, 2004·Journal of Gastroenterology and Hepatology·Anna C Casburn-Jones, Michael J G Farthing
Oct 20, 2004·East African Medical Journal·P K FegloM Essel-Ahun
Jul 19, 2006·Clinical Microbiology Reviews·David J Diemert
Oct 1, 1996·Journal of Food Protection·Roger P JohnsonCarlton L Gyles

❮ Previous
Next ❯

Citations

Feb 27, 2015·Antimicrobial Resistance and Infection Control·Sylvia OmuloDouglas R Call
Jan 28, 2014·Journal of Urban Health : Bulletin of the New York Academy of Medicine·Charles OchodoJ O Otieno
May 19, 2010·Epidemiology and Infection·R M MurithiM Kariuki Njenga

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Amoebiasis

Amoebiasis, infection by the protozoan parasite Entamoeba histolytica, remains a global health problem, despite the availability of effective treatment. Here is the latest research.

Antibodies: Agglutination

Antibody-mediated agglutination is the clumping of cells in the presence of antibody, which binds multiple cells together. This enhances the clearance of pathogens. Find the latest research on antibody-mediated agglutination here.

Ascariasis (ASM)

Ascariasis is a helminthic infection of global distribution with more than 1.4 billion persons infected throughout the world. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Ascariasis

Ascariasis is a helminthic infection of global distribution with more than 1.4 billion persons infected throughout the world. Here is the latest research.